Upfront immunosuppression regimen improves survival in acquired haemophilia A
05 Jul 2026
bởiJairia Dela Cruz
In the first-line treatment of acquired haemophilia A (AHA), the use of an intravenous (IV) pulse-dose immunosuppression regimen that combines cyclophosphamide, dexamethasone, and rituximab appears to result in faster remission and improved survival compared with traditional oral sequential prednisone-based regimens, according to a study.